Born out of Omega push for pandemic treatments, Aerium Therapeutics enters long Covid R&D

Aerium Therapeutics, which Omega Funds seeded in 2021 and unveiled in spring 2022 to take on Covid-19 with new monoclonal antibodies, will attempt to treat long Covid with a Phase II trial set to start later this month.

The move comes as the National Institutes of…
Click here to view original post

Advertisement — Advertise with Biotech Networks